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1. Introduction 
Since 2000, 16 WHO External Quality Assurance System (EQAS) reports have been issued with 
this report being the 17th. The WHO Global Foodborne Infections Network (WHO GFN) and the 
WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) focus on 
enhancing World Health Organization (WHO) Member States’ capacity to detect and respond to 
foodborne disease outbreaks and the emerging of antimicrobial resistance (AMR) in bacterial 
pathogens by conducting laboratory-based surveillance of Salmonella and other important 
foodborne pathogens. Thus, the WHO EQAS 2017 aligns with the 2015 WHO global action plan to 
target AMR worldwide, objective 2: Strengthen knowledge through surveillance and research, 
action 2, laboratory capacity.  
Since its inception, the scope of the WHO EQAS has expanded to include additional foodborne 
pathogens than Salmonella such as Shigella and Campylobacter. Salmonella, Campylobacter and 
Shigella are among the most important foodborne pathogens worldwide and accounts for millions 
of cases of diarrheal disease and thousands of deaths per year impacting both developing and 
industrialized countries. Furthermore, the increased number of Salmonella, Campylobacter and 
Shigella isolates which are resistant to antimicrobials is of major concern since these bacterial 
isolates are associated with infections characterized by increased morbidity and mortality.  
In the 2017 iteration of the WHO EQAS, a major change was applied as it focuses only on 
Salmonella serotyping and antimicrobial susceptibility testing (AST). This adjustment was made to 
balance the costs and focus efforts at continuing the development of the genomic proficiency test 
adopted by WHO and offered through the Global Microbial Identifier (GMI) 
(http://www.globalmicrobialidentifier.org/workgroups/about-the-gmi-proficiency-tests). 
The WHO EQAS is organized annually by DTU Food in collaboration with World Health 
Organization (WHO) in Geneva, Switzerland, Centers for Disease Control and Prevention (CDC) in 
Atlanta, USA, and Institute Pasteur (IP) in Paris, France.  
Individual laboratory data are confidential and known only by the participating laboratory, the 
EQAS Organizer (DTU Food) and possibly the respective WHO GFN regional centre/WHO 
AGISAR country representative. All summary conclusions are public. The goal set by WHO 
GFN/AGISAR aims at having all national reference laboratories perform Salmonella serotyping 
with a maximum of one deviation out of eight strains tested (error rate of 13%) and performing 
AST of Salmonella with a maximum error rate of 10% (either less than 5% very major / major 
errors and less than 5% minor errors, or less than 10% minor errors). Minor deviations are defined 
as classification of an intermediate strain as susceptible, resistant or vice versa (i.e. I ↔ S or I ↔R). 
Major deviation is the classification of a susceptible strain as resistant (i.e. S → R). Very major 
deviation is the classification of a resistant strain as susceptible (i.e. R → S). In this report, the 
deviations of AST results are divided into two categories, i.e. critical deviations which include 
major and very major deviations, and total deviations which include also the minor deviations. In 
EQAS 2014, the regions were re-defined for all countries worldwide in relation to the analysis of 
data from the WHO GFN EQAS. This resulted in some reorganization of countries into new regions 
compared to previous years, why interpretation of regional-based results from 2014 and onwards 
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with results from before 2014 should be conducted with care. The countries belonging to each 
region is listed in Appendix 1. 
Appendices 2-5 present additional background information in relation to the WHO EQAS 2017. 
 
2. Summary 
The summary report is divided into sections; the serotyping component, AMR as well as reporting 
resistance to Extended Spectrum Beta-Lactamases (ESBL) producing Salmonella. All results 
reported in the summary can be found in Appendix 1. 
 
Participation 
A total of 191 laboratories responded to the pre-notification and were enrolled in the WHO EQAS. 
When the deadline for submitting results was reached, 181 laboratories in 81 countries had 
uploaded data. 
The following countries provided data for at least one of the EQAS components (Appendix 1): 
Argentina, Australia (3), Bahrain, Bangladesh, Barbados, Belgium, Belize, Bolivia, Brazil (2), 
Brunei Darussalam, Bulgaria, Cambodia, Cameroon, Canada (11), Chile, China (15), Colombia (4), 
Costa Rica (2), Croatia, Cuba, Curaçao, Cyprus, Czech Republic (2), Denmark, Ecuador, Egypt, 
Gambia, Germany (2), Ghana, Greece (2), Guatemala (2), Honduras, India (4), Iran, Islamic rep. of 
(3), Ireland, Israel, Italy (14), Jamaica, Japan (2), Kenya (2), Korea, Rep of (2), Kosovo, Lao PDR, 
Luxembourg (2), Madagascar, Malaysia (5), Malta, Mauritius, Mexico (3), Morocco, Nepal (6), 
New Zealand, Nigeria (4), Panama (2), Paraguay, Peru, Philippines (2), Poland (3), Portugal, Serbia 
(2), Singapore (2), Slovakia, Slovenia, South Africa, Spain, Sri Lanka (2), Suriname, Sweden, 
Taiwan, Tanzania, United Republic of, Thailand (16), Trinidad and Tobago, Turkey, Ukraine, 
United Kingdom, United States of America (5), Uruguay, Venezuela (2), Viet Nam (2), Zambia, 
and Zimbabwe. 
The level of participation in the WHO EQAS 2017 was the same as at the WHO EQAS 2016.  
 
Salmonella EQAS components 
The acceptance threshold for the EQAS Salmonella serotyping component was met by 77% (n = 
111) of the 145 participating laboratories (Table 1). In addition, 88% (n = 127) of the laboratories 
tested all eight strains with a total of 90% (n = 1.014) of all tests being correct, representing results 
almost at the same level as in 2016 which was one of the best performances observed since the 
initiation of the EQAS (Table 2). The ability to correctly serotype the internal control strain 
increased in 2017 to the same level as in 2014, 98%, which is the best performance, recorded and 
only observed previously in 2011 and 2014. The increase in performance observed compared to 
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2016 was most likely due to a lower number of participating laboratories serotyping this specific 
strain. In 2017, the participation in testing the internal control strain decreased from 159 to 142, a 
level previously recorded over the years (Table 3). On a region-based categorization of participating 
laboratories, Africa and the Central Asia & Middle East both correctly serotyped between 63% and 
66% of the test strains whereas the Caribbean, Southeast Asia, and Latin America, correctly 
serotyped between 81% and 89% of the test strains. The performance of correct serotyping in 
Europe, China, North America was between 94 and 99% but reached 100% correct serotyping of all 
eight strains in only Oceania. In 2017, Russia was again the only region not participating (Table 4). 
In all regions except for the Central Asia & Middle East region either a marked or consistent 
improvement was observed and in line with the other data presented. 
In 2017, the main problem regarding the Salmonella serotyping appeared relatively to be associated 
with strain, WHO 2017 S-17.8 (Kentucky) whereas the deviations for the rest of the strains seems to 
be acceptable at a level of approximately 10% (n=5) and for the remaining two strains at 6% and 
2%.   
As indicated, WHO 2017 S-17.8 (Kentucky, I 8,20:i:z6), revealed a considerable level of deviation 
at 17.0% (Table 5). Of the 23 deviations, 14 were attributed to Tumodi (I 1,4,12:i:z6) which only 
differs from the somatic O antigen compared to Kentucky. It is surprising that the problem of the 
serotyping procedure seems very often to be associated with the somatic O antigen of relatively 
common antigens. The level of deviation is surprising since the serovars included the 2017 should 
not pose major difficulties. The somatic O antigens of all the test strains belong to the major 
serogroups such as O:4, O:3,10, O:7, O:8, and O:9, and the flagella antigens belong to well-known 
polyvalent antisera complex G and HMD.  
Concerning the Salmonella AST component for the EQAS 2017, the performance slightly 
decreased compared to the EQAS of 2016, with deviations of 3% minor, 2% major, and 3% very 
major deviations. Thus, the percentages of critical deviation was 5% (Table 6). Deviations 
categorized by the tested antimicrobials revealed that ceftazidime (CAZ), ciprofloxacin (CIP), 
colistin (COL), ceftriaxone (CRO), cefotaxime (CTX), meropenem (MERO), sulfamethoxazole 
(SMX) and co-trimoxazole (SXT) caused most of the difficulties observed with the following level 
of total deviations: 22%, 18%, 6%, 7%, 8%, 6%, 7%, and 7%, respectively (Table 7). The 
deviations to CIP was mostly attributed to minor deviations and most likely due to the often 
observed hazy double zone when performing disk diffusion where the outer zone often incorrectly 
is measured. In this year’s iteration, participating laboratories appears to have been too strict 
measuring the zone diameter categorizing the susceptible strains intermediate. Similarly, the 
deviations observed to SMX and SXT are due to the bacteriostatic effect complicating reading when 
conducting both disk diffusion and minimum inhibitory concentration (MIC) determination where 
20% of the lawn of growth for disk diffusion equal to 80% reduction of growth for MIC 
determination determines the read-value. This year, a resistant isolate caused most problems. For 
the disk diffusion results, it was not surprising to see deviations in relation to COL as disk diffusion 
is not recommended as a method for AST to colistin. This resulted in 10 participants incorrectly 
reporting one isolate susceptible despite it being resistant. For the four antimicrobials used to 
confirm ESBL and carbapenemase production, CAZ, CRO, CTX and MERO, all were responsible 
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for critical deviations with 17% of all tests incorrect for CAZ, which is a great concern (Table 7, 
Table 8). Assessing the data for the four antimicrobials, no clear patterns was observed, resistance 
reported as susceptible and visa versa (Table 8).  
On a region-based categorization of participating laboratories, all regions performed poorly 
compared to 2016. A greater number of deviations was observed in developing regions, which 
partly could explain the results as well as the difficulties reporting the results for the third 
generation cephalosporins. The Caribbean region obtained the highest percentages of total 
deviations, 24.3% whereas a number of regions obtained a total deviations around 10%, i.e. Africa 
(12.8%), China (6.6%), Southeast Asia (8.1%), Latin America (8.9%), Europe (7.2%), and Central 
Asia & Middle East (11.1%). None of the regions obtained a performance of 100% correct AST 
results, however, North America and Oceania performed better than the other regions with 97.1% 
and 96.1% correct AST-results. Russia did not participate in the 2017 EQAS (Table 9). 
For the 150 laboratories performing the Salmonella AST component (MIC (n = 41)/Disk diffusion 
(n = 74)), only 77% (115 laboratories) reported data for AST of the control strain E. coli ATCC 
25922. As in previous years, this is a very alerting number as it is expected that all participating 
laboratories follow quality assurance procedures (Table 10). It is of extreme importance to once 
again emphasize that this component represents the true indicator for the laboratory as to the 
performance of AST. It is noteworthy that the WHO EQAS organizers provide the control strain E. 
coli ATCC 25922 free of charge to all new participants of the AST component, why there should 
not be any excuses not to test this strain.  
ESBL EQAS component 
The participants of the AST component are offered to detect and confirm ESBL production in the 
Salmonella strains. If participating in this component of the EQAS, all strains showing reduced 
susceptibility to cefotaxime (CTX), cefoxitin (FOX), ceftazidime (CAZ) ceftriaxone (CRO) and/or 
meropenem (MERO) should be tested for ESBL, AmpC and carbapenemase production. 
For the EQAS 2017, four AmpC-, ESBL-, carbapenemase-producers were included represented by 
WHO 2017 S-17.1 Infantis (ESBL), WHO 2017 S-17.2 Havana (AmpC), WHO 2017 S-17.4 Rissen 
(ESBL), and WHO 2017 S-17.8 Kentucky (carbapenemase producers) (Table 11). The two ESBL 
producing strains harboured the blaCTX-M14b, and blaCTX-M14 genes whereas the gene accounting for 
the AmpC phenotype till now curiously is unknown.  The carbapenemase producer was conferred 
by blaNDM-1 and blaCMY-16. The confirmatory tests (CAZ/Cl:CAZ and CTX/Cl:CTX) showed 87% 
(WHO 2017 S-17.1) and 90% (WHO 2017 S-17.4) of deviations in reporting correct ESBL results 
(based on phenotypic characteristics). For the WHO 2017 S-17.2 (AmpC) and WHO 2017 S-17.4 
(carba), deviations of the confirmatory test resulted in 66% and 34%. In general, the level of 
correctly identified ESBL, AmpC and carbapenemase producing Salmonella is a great concern and 
it is suggested that the participating laboratories take steps to ensure that it is improved. 
___   ___   ___ 
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Figure and Tables 
 
Figure 1. Countries participating* in the WHO EQAS 2017 
*marked in green
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List of Countries in the 10 Regions 
 
Africa 
Algeria Gabon Reunion 
Angola Gambia Rwanda 
Benin Ghana Saint Helena 
Botswana Guinea Sao Tome and Principe 
Burkina Faso Guinea-Bissau Senegal 
Burundi Kenya Seychelles 
Cameroon Lesotho Sierra Leone 
Cameroun Liberia Somalia 
Cape Verde Libyan Arab Jamahiriya South Africa 
Central African Republic Madagascar South Sudan 
Chad Malawi Sudan 
Comoros Mali Swaziland 
Congo (Brazzaville) Mauritania Tanzania, United Republic of 
Congo, Democratic Republic of the Mauritius Togo 
Cote d'Ivoire (Ivory Coast) Mayotte Tunisia 
Djibouti Morroco Uganda 
Egypt Mozambique Western Sahara 
Equatorial Guinea Namibia Zambia 
Eritrea Niger Zimbabwe 
Ethiopia Nigeria  
 
Caribbean 
Anguilla Dominica Saint Martin 
Antigua and Barbuda Dominican Republic Saint Vincent and the Grenadines 
Aruba Grenada Saint-Barthélemy 
Bahamas Guadeloupe Sint Maarten 
Barbados Haiti St. Kitts and Nevis 
Bonaire, Saint Eustatius and Saba Jamaica Trinidad and Tobago 
British Virgin Islands Martinique Turks and Caicos Islands 
Cayman Islands Monserrat Virgin Islands (US) 
Cuba Puerto Rico  
Curaçao Saint Lucia  
 
Central Asia & Middle East 
Afganistan Israel Pakistan 
Armenia Jordan Palestine 
Azerbaijan Kazakhstan Qatar 
Bahrain Kuwait Saudi Arabia 
Bangladesh Kyrgyzstan Syria 
Bhutan Lebanon Tajikistan 
Georgia Macao Timor Leste (West) 
Hong Kong Maldives Turkmenistan 
India Mongolia United Arab Emirates 
Indonesia Myanmar (ex-Burma) Uzbekistan 
Iran, Islamic rep. Of Nepal Yemen 
Iraq Oman  
 
China 
China 
 
Europe 
Albania Guerney and Alderney Norway 
Andorra Hungary Poland 
Austria Iceland Portugal 
Belarus Ireland Romania 
Appendix 1 – Figure and Tables, page 3 of 20 
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Belgium Italy San Marino 
Bosnia Jersey Serbia 
Bulgaria Kosovo Slovak Republic 
Croatia Latvia Slovakia 
Cyprus Liechtenstein Slovenia 
Czech Republic Lithuania Spain 
Denmark Luxembourg Svalbard and Jan Mayen Islands 
Estonia Macedonia Sweden 
European Union Malta Switzerland 
Faroe Islands Man, Island of Turkey 
Finland Moldova Ukraine 
France Monaco United Kingdom 
Germany Montenegro Vatican City State (Holy See) 
Gibraltar Netherlands  
Greece   
 
Latin America 
Argentina El Salvador Nicaragua 
Bolivia Falkland Islands (Malvinas) Panama 
Brazil French Guiana Paraguay 
Chile Guatemala Peru 
Colombia Guyana Suriname 
Costa Rica Honduras Uruguay 
Ecuador Mexico Venezuela 
 
North America 
Bermuda Greenland United States of America 
Canada Saint Pierre and Miquelon  
 
Oceania 
Australia Papua New Guinea Guam 
Kiribati Tonga New Caledonia 
New Zealand French Polynesia Samoa, American 
Solomon, Islands Micronesia Vanuatu 
Fiji Samoa  
Marshall Islands Tuvalu  
 
Russia 
Russia  
 
Southeast Asia 
Brunei Darussalam Lao PDR Taiwan 
Cambodia Malaysia Thailand 
Japan Philippines Viet Nam 
Korea, North Singapore  
Korea, Rep of Sri Lanka  
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Table 1. Ability of EQAS participating laboratories to serotype the test Salmonella strains  
 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2000 
EQAS 
2001 
EQAS 
2002 
EQAS 
2003 
EQAS 
2004 
EQAS 
2006 
EQAS 
2007 
No. % No. % No. % No. % No. % No. % No. % 
8 9 24 34 35 52 53 66 47 41 32 42 32 66 47 
7 9 24 13 14 19 19 29 21 14 11 35 27 29 21 
6 4 11 9 9 12 12 13 9 16 13 19 15 13 9 
5 3 8 9 9 4 4 11 8 16 13 12 9 11 8 
4 3 8 4 4 1 1 7 5 11 9 7 5 7 5 
3 4 11 8 8 4 4 6 4 10 8 5 4 6 4 
2 2 5 3 3 5 5 2 1 10 8 3 2 2 1 
1 2 5 5 5 1 1 6 4 5 4 4 3 6 4 
0 1 3 11 11 1 1 0 0 4 3 3 2 0 0 
In total 37 100 96 100 99 100 127 100 127 100 130 100 140 100 
 
Participating laboratories 
EQAS 
2008 
EQAS 
2009 
EQAS 
2010 
EQAS 
2011 
EQAS 
2012 
EQAS 
2013 
EQAS 
2014 
No. % No. % No. % No. % No. % No. % No. % 
8 50 33 76 50 91 61 82 67 68 47 52 41 70 47 
7 36 24 29 19 16 11 17 14 29 20 29 23 32 21 
6 11 7 7 5 12 8 10 8 14 10 15 12 17 11 
5 14 9 13 8 9 6 2 2 9 6 8 6 6 4 
4 12 8 5 3 6 5 4 3 5 3 7 6 5 3 
3 9 6 7 5 2 1 4 3 6 4 7 6 7 5 
2 8 6 5 3 2 1 1 1 10 7 6 5 4 3 
1 9 6 6 4 7 5 3 2 2 1 2 2 4 3 
0 2 1 5 3 3 2 0 0 1 1 0 0 4 3 
In total 151 100 153 100 148 100 123 100 144 100 126 100 149 100 
 
Participating laboratories 
EQAS 
2015 
EQAS 
2016 
EQAS 
2017 
Average 
EQAS 
2000 - 
2017 
   
No. % No. % No. % No. %       
8 65 43 84 58 85 59 61 46       
7 25 17 22 15 26 18 24 19       
6 17 11 18 12 14 10 13 10       
5 22 15 5 3 7 5 9 7       
4 5 3 5 3 5 3 6 5       
3 2 1 5 3 3 2 6 5       
2 4 3 3 2 0 0 4 3       
1 7 5 4 3 4 3 5 4       
0 4 3 0 0 1 1 2 2       
In total 151 100 146 100 145 100 129 100       
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Table 2. EQAS participating laboratories’ performance of Salmonella serotyping  
 
EQAS 
iteration 
 
Labs serotyping all 
provided strains Correct test results 
No. % No. % 
2000 34 92 165 76 
2001 79 82 513 72 
2002 80 81 668 91 
2003 69 54 692 80 
2004 78 61 701 81 
2006 105 81 808 85 
2007 109 78 920 88 
2008 100 66 888 83 
2009 119 83 974 86 
2010 129 87 998 89 
2011 109 89 878 92 
2012 122 81 936 83 
2013 74 59 812 89 
2014 85 57 969 92 
2015 104 69 948 87 
2016 130 89 1004 90 
2017 127 88 1014 90 
Average 101 76 817 86 
 
Table 3. EQAS participating laboratories’ performance of internal quality control strain  
(WHO S-17.3, Salmonella Enteritidis) serotyping). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EQAS 
iteration 
Labs serotyping  
S. Enteritidis correctly 
No. % 
2000 34 92 
2001 64 84 
2004 113 95 
2006 116 94 
2007 135 96 
2008 139 96 
2009 141 93 
2010 138 97 
2011 128 98 
2012 139 96 
2013 130 96 
2014 145 98 
2015 125 93 
2016 159 89 
2017 142 98 
Average 123 94 
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Table 4. Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
Region EQAS iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
in EQAS 2017 
A
fr
ic
a 
2001 6 37 73.0 
Cameroun, Egypt, Kenya, 
Madagascar, Mauritius, 
Morocco, Nigeria (2), South 
Africa 
2002 9 62 87.1 
2003 11 70 71.4 
2004 9 51 62.7 
2006 16 95 71.6 
2007 11 73 80.8 
2008 10 71 49.3 
2009 15 94 75.5 
2010 13 83 67.5 
2011 10 57 79.2 
2012 10 65 60.0 
2013 8 51 74.5 
2014 11 63 76.2 
2015 12 68 61.8 
2016 8 58 62.1 
2017 9 56 62.5 
C
en
tr
al
 A
sia
 &
  
M
id
dl
e 
Ea
st
  
2001 10 60 50.0 
Bahrain, India, Israel, Nepal 
2002 5 30 83.3 
2003 5 35 54.3 
2004 5 33 54.5 
2006 5 35 74.3 
2007 5 40 55.0 
2008 5 34 61.8 
2009 5 32 46.9 
2010 5 22 75.9 
2011 3 23 95.8 
2012 4 30 56.7 
2013 5 38 52.6 
2014 7 37 75.7 
2015 7 44 77.3 
2016 5 38 78.9 
2017 4 32 65.6 
C
ar
ib
be
an
 
2001 0 0 0 
Barbados, Cuba, Curaçao, 
Trinidad and Tobago 
2002 0 0 0 
2003 3 18 61.1 
2004 2 8 87.5 
2006 3 14 78.6 
2007 2 9 77.8 
2008 3 14 78.6 
2009 3 12 83.3 
2010 2 13 92.9 
2011 1 7 87.5 
2012 2 16 62.5 
2013 1 5 100.0 
2014 3 15 60.0 
2015 5 24 58.3 
2016 2 16 60 
2017 4 32 81.3 
Eu
ro
pe
 
2001 43 323 80.5 
Belgium, Bulgaria, Croatia, 
Cyprus, Czech Republic (2), 
Denmark, Germany (2), Greece 
(3), Ireland, Italy (14), 
Luxembourg (2), Poland (3), 
Portugal, Serbia (2), Slovak 
Republic, Slovenia, Spain, 
Sweden, Turkey, Ukraine, 
United Kingdom 
2002 50 384 90.0 
2003 60 401 84.8 
2004 57 392 84.7 
2006 52 403 86.4 
2007 54 415 89.4 
2008 50 379 82.3 
2009 47 362 93.1 
2010 45 332 94.1 
2011 42 314 94.6 
2012 47 368 92.9 
2013 42 309 94.5 
2014 52 391 96.2 
2015 48 371 93.8 
2016 46 362 93.4 
2017 42 330 93.6 
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Table 4 (continued). Region-based categorization of EQAS participants’ performance of  
Salmonella serotyping 
Region EQAS iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
 in EQAS 2017 
N
or
th
 A
m
er
ic
a 
 
2001 4 32 87.5 
Canada (9), United States of 
America (4) 
2002 2 16 100.0 
2003 6 41 95.1 
2004 8 55 81.8 
2006 10 80 96.3 
2007 12 94 97.9 
2008 11 84 95.2 
2009 12 90 92.2 
2010 13 103 100.0 
2011 11 81 97.6 
2012 14 101 93.1 
2013 13 92 97.8 
2014 13 84 100.0 
2015 13 93 100.0 
2016 13 100 99.0 
2017 13 99 99.0 
O
ce
an
ia
  
2001 4 30 100.0 
Australia (3), New Zealand 
2002 6 43 93.0 
2003 6 46 93.5 
2004 5 38 97.4 
2006 5 37 94.6 
2007 4 32 100.0 
2008 4 30 93.3 
2009 4 32 96.9 
2010 4 32 100.0 
2011 4 32 100.0 
2012 4 32 100.0 
2013 4 31 100.0 
2014 4 32 100.0 
2015 4 31 100.0 
2016 4 32 100.0 
2017 4 31 100.0 
R
us
sia
 
2001 1 8 12.5 
- none - 
2002 1 8 62.5 
2003 1 7 14.3 
2004 4 26 69.2 
2006 5 40 80.0 
2007 8 51 80.4 
2008 6 40 90.0 
2009 7 49 91.8 
2010 8 54 87.1 
2011 7 48 87.3 
2012 6 48 87.5 
2013 2 16 75.0 
2014 4 30 93.3 
2015 3 24 100.0 
2016 - - - 
2017 - - - 
La
tin
 A
m
er
ic
a 
 
2001 11 78 57.7 
Argentina, Bolivia, Brazil (2), 
Chile, Colombia (4), Costa Rica 
(2), Ecuador, Guatemala, 
Honduras, Mexico (3), Panama 
(2), Paraguay, Peru, Uruguay, 
Venezuela 
2002 11 82 87.8 
2003 13 83 75.9 
2004 15 88 79.5 
2006 13 84 84.5 
2007 15 107 88.8 
2008 17 120 71.7 
2009 21 150 77.3 
2010 22 132 80.0 
2011 23 144 83.7 
2012 25 182 73.1 
2013 22 154 83.1 
2014 24 166 84.9 
2015 20 133 84.2 
2016 23 165 87.9 
2017 23 178 89.3 
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Table 4 (continued). Region-based categorization of EQAS participants’ performance of  
Salmonella serotyping 
 
 
  Region EQAS iteration No. of labs 
No. of strains 
serotyped  
% strains correctly 
serotyped 
Countries participating 
 in EQAS 2017 
So
ut
he
as
t A
sia
  
2001 15 113 54.0 
Brunei Darussalam, Cambodia, 
Japan (2), Korea, Rep of (2), 
LAO PDR, Malaysia (4), 
Philippines (2), Singapore (2), 
Sri Lanka, Taiwan, Thailand 
(12), Viet Nam (2) 
2002 12 90 92.2 
2003 15 100 81.0 
2004 17 130 81.5 
2006 15 117 84.6 
2007 19 140 91.4 
2008 18 125 81.6 
2009 23 180 81.1 
2010 24 172 90.5 
2011 23 180 98.4 
2012 28 207 77.8 
2013 22 163 89.6 
2014 22 166 94.6 
2015 24 179 88.3 
2016 28 211 87.7 
2017 31 244 89.3 
C
hi
na
  
2001 4 32 96.9 
China (15) 
2002 3 24 100.0 
2003 8 60 75.0 
2004 7 46 78.3 
2006 6 48 85.4 
2007 10 80 91.3 
2008 15 108 94.4 
2009 16 126 95.2 
2010 10 74 92.5 
2012 10 78 80.8 
2013 7 54 92.6 
2014 9 71 93.0 
2015 15 118 78.0 
2016 17 136 95.6 
2017 15 120 97.5 
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Table 5. Salmonella serogroups (SG), serotypes (ST) and deviations (D), WHO EQAS 2017 
 
*number of participants reporting the specified deviating result 
 
Strain 
ID Correct serotype 
No. of labs 
reporting 
SG 
% DSG 
No. of labs 
reporting 
ST 
% DST Deviating results (*) 
WHO 
2017 
S-17.1 
Infantis I 6,7:r:1,5 159 4.4 143 11.2 
Choleraesuis (2), Goma, Irumu, Papuana, Paratyphi A, Paratyphi C, 
Surat, Thompson, Typhi, Virchow (6) 
WHO 
2017 
S-17.2 
Havana I 13,23:f,g:- 149 10.7 137 10.9 
Adelaide, Derby, II .1.,13,23:g,m,[s],t:[e,n,x], Kiel, Linton, Lomita, 
Paratyphi A, Paratyphi C, Raus (3), Rideau (2), Rissen, Rissen var. 
14+ 
WHO 
2017 
S-17.3 
Enteritidis I 9,12:g,m;- 156 1.3 142 2.1 
Berta, Typhi (2) 
WHO 
2017 
S-17.4 
Rissen I 6,7:f,g:- 152 1.3 139 10.1 
Alamo, Eingedi (2), Galiema, Menston, Montevideo, Othmarschen 
(4), Plumaugat, Typhi 
WHO 
2017 
S-17.5 
Weltevreden I 3,10:r;z6 155 2.6 142 9.2 
Assinie, Dumfries, Elisabethville (3), Fareham, Paratyphi B (2), Simi, 
Stockholm, Ughelli (2) 
WHO 
2017 
S-17.6 
Schwarzengrund I 4,12:d:1,7 156 1.3 141 10.6 
Ahmadi, Ayinde, Brezany, Kisangani, Kubacha, Kaapstad, Paratyphi 
A, Paratyphi B, Sarajane, Stanley (2), Travis, Typhimurium (2), 
Uppsala 
WHO 
2017 
S-17.7 
Typhimurium I 4,5,12:i;1,2 157 1.3 143 6.3 
Avonmouth, I 1,4,5,12:i:, Lagos (3), Paratyphi A, Saintpaul 
WHO 
2017 
S-17.8 
Kentucky I 8,20:i:z6 145 15.9 135 17.0 
Azteca, Bardo, Bargny, Enteritidis, Falkensee, Haardt, Paratyphi A 
(2), Sekondi, Tumodi (14) 
 
 
 
Table 6. EQAS participating laboratories’ performance of antimicrobial susceptibility testing of Salmonella strains 
 
EQAS 
iteration 
No. of EQAS 
participating 
laboratories  
% correct test 
results 
 
% minor deviations 
(S ↔ I or I ↔ R)^  
% major 
deviations 
(S → R)^ 
% very major 
deviations  
(R→ S)^ 
% critical deviations 
(R→ S & S → R)^ 
% total deviations 
(S → R & R → S & S ↔ 
I or I ↔ R)^ 
2000 44 92 4 4 0 4 8 
2001 108 91 6 2 1 3 9 
2002 119 92 6 2 1 3 9 
2003* 147 93 4 3 0 3 7 
2004 152 93 4 2 1 3 7 
2006 143 88 8 3 1 4 12 
2007 143 93 4 2 1 3 7 
2008 168 91 4 2 3 5 9 
2009 153 94 3 2 1 3 6 
2010 152 92 4 3 2 5 8 
2011 127 91 4 2 3 5 9 
2012 159 94 3 2 1 3 6 
2013 145 95 3 2 0 2 5 
2014 155 95 3 1 1 2 5 
2015 155 92 4 2 1 4 8 
2016 150 95 2 2 1 3 5 
2017 150 91 3 2 3 5 8 
Average* 139 93 4 2 1 4 8 
*Data do not include one strain which may have lost resistance due to transport or storage stress 
^S, susceptible; I, intermediate; R, resistant 
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Table 7. EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. 
of 
labs 
Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP COL CRO CTX GEN KAN NAL SMX MER STR SXT TET TMP XNL OVERALL average 
2000 44 
No. of tests - 343 - 343 334 - - - 343 312 328 248 - 312 - 335 295 - 798 
% critical deviations* - 6 - 4 1 - - - 4 4 1 3 - 4 - 6 1 - 6 
% total deviations^ - 8 - 7 6 - - - 5 16 4 5 - 12 - 13 1 - 14 
2001 108 
No. of tests - 822 - 814 813 - - - 821 623 726 431 - 679 757 804 416 - 1778 
% critical deviations*  - 4 - 2 1 - - - 2 2 2 6 - 7 2 7 1 - 6 
% total deviations^ - 7 - 3 4 - - - 4 7 8 9 - 27 5 18 2 - 15 
2002 119 
No. of tests - 918 - 903 911 - - - 905 680 885 495 - 718 724 861 499 - 1961 
% critical deviations* - 2 - 2 0 - - - 2 2 2 4 - 4 7 3 3 - 5 
% total deviations^ - 3 - 3 2 - - - 16 10 4 4 - 34 10 7 3 - 15 
2003● 147 
No. of tests - 1019 - 996 995 - - - 993 738 947 615 - 768 929 995 582 - 2210 
% critical deviations* - 2 - 1 0 - - - 2 2 1 4 - 9 2 4 1 - 5 
% total deviations^ - 4 - 2 1 - - - 2 6 4 5 - 39 2 11 1 - 12 
2004 152 
No. of tests 973 1178 - 1159 1162 - - 995 1201 - 1130 734 - 947 1051 1122 729 - 2653 
% critical deviations* 6 3 - 2 0 - - 0 2 - 1 5 - 1 3 5 2 - 5 
% total deviations^ 12 5 - 2 1 - - 14 3 - 4 8 - 21 4 11 2 - 13 
2006 143 
No. of tests 950 1092 769 1060 1110 - - 956 1078 - 1035 649 - 896 996 1054 607 225 2256 
% critical deviations* 9 2 7 3 2 - - 7 3 - 2 6 - 5 3 9 1 2 8 
% total deviations^ 22 3 11 15 6 - - 15 7 - 6 7 - 22 5 20 2 9 21 
2007 143 
No. of tests 908 1114 830 1105 1101 - - 914 1111 - 1092 678 - 875 971 1047 583 258 2290 
% critical deviations* 6 5 1 0 1 - - 1 3 - 2 5 - 4 3 4 1 0 5 
% total deviations^ 17 7 1 6 1 - - 2 4 - 3 6 - 26 3 11 2 6 13 
2008 168 
No. of tests - 1331 961 1226 1307 - 791 1104 1265 - 1168 718 - 867 1155 1249 696 - 2769 
% critical deviations* - 3 3 1 19 - 3 3 4 - 2 4 - 7 3 6 2 - 8 
% total deviations^ - 8 6 11 21 - 6 6 6 - 4 5 - 25 4 13 2 - 16 
2009 153 
No. of tests - 1206 921 1108 1190 - 775 1009 1143 - 1095 624 - 864 1042 1114 616 - 2541 
% critical deviations* - 3 1 1 8 - 0 1 2 - 1 7 - 9 3 4 1 - 6 
% total deviations^ - 6 1 2 10 - 1 2 3 - 3 9 - 30 4 10 1 - 11 
2010 152 
No. of tests - 1173 937 1118 1194 - 787 1026 1133 - 1096 566 - 800 1012 1134 604 - 2516 
% critical deviations* - 4 2 1 3 - 4 4 5 - 1 14 - 19 4 5 1 - 9 
% total deviations^ - 5 3 2 3 - 8 8 6 - 2 17 - 55 4 9 1 - 17 
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Table 7 (continued). EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial. 
 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R, resistant; S, susceptible) 
^S→R & R→S & S↔I or I↔R (I, intermediate) 
● Data do not include one strain which may have lost resistance due to transport or storage stress 
-, not determined 
EQAS 
iteration 
No. 
of 
labs 
Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP COL CRO CTX GEN KAN NAL SMX MER STR SXT TET TMP XNL OVERALL Average 
2011 127 
No. of tests - 1099 829 988 1070 - 744 909 999 - 993 542 - 682 988 1017 493 - 2271 
% critical deviations* - 5 3 2 20 - 3 4 4 - 7 4 - 3 3 4 1 - 9 
% total deviations^ - 6 4 2 21 - 3 6 5 - 15 5 - 42 3 10 2 - 17 
2012 159 
No. of tests - 1228 993 1159 1245 - 834 1058 1161 - 1136 584 - 814 1054 1163 613 - 2608 
% critical deviations* - 3 2 1 11 - 2 4 3 - 2 5 - 2 1 2 1 - 5 
% total deviations^ - 5 2 2 12 - 3 5 4 - 4 7 - 35 2 5 1 - 12 
2013 145 
No. of tests - 1121 898 1027 1134 - 763 1011 1086 - 1027 491 - - 946 1060 545 - 2381 
% critical deviations* - 2 3 0 2 - 1 3 3 - 2 4 - - 2 3 2 - 4 
% total deviations^ - 3 3 1 18 - 2 6 6 - 6 5 - - 2 5 2 - 9 
2014 155 
No. of tests - 1176 1003 1072 1161 - 817 1014 1147 - 1078 561 - - 1039 1107 541 - 2511 
% critical deviations* - 3 3 1 3 - 1 2 3 - 1 5 - - 2 3 2 - 4 
% total deviations^ - 4 4 2 19 - 2 3 5 - 2 6 - - 3 5 2 - 9 
2015 155 
No. of tests - 1176 1010 1064 1172 - 787 1018 1145 - 1010 514 611 - 1034 1077 591 - 2468 
% critical deviations* - 3 9 2 1 - 3 5 3 - 4 7 1 - 2 2 2 - 6 
% total deviations^ - 5 11 22 14 - 4 6 5 - 10 9 1 - 3 5 2 - 13 
2016 150 
No. of tests - 1133 988 1020 1100 - 800 968 1104 - 959 529 838 - 953 1042 599 - 2407 
% critical deviations* - 4 4 1 1 - 2 4 4 - 1 7 5 - 2 3 2 - 8 
% total deviations^ - 5 4 2 10 - 3 4 6 - 3 8 6 - 2 6 2 - 12 
2017 150 
No. of tests - 1166 1016 881 1167 473 831 968 1113 - 921 487 921 - 1055 1014 553 - 1354 
% critical deviations* - 4 17 4 1 6 6 6 4 - 2 5 6 - 6 2 5 - 3 
% total deviations^ - 5 22 5 18 6 7 8 5 - 2 7 6 - 7 4 5 - 9 
Average● 139 
No. of tests 944 1076 930 1003 1069 473 793 996 1044 588 978 557 790 769 982 1011 562 242 800 
% critical deviations* 7 3 5 2 4 6 3 3 3 3 2 6 4 6 3 4 2 1 4 
% total deviations^ 17 5 6 4 10 6 4 7 5 10 5 7 4 31 4 10 2 8 8 
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Table 8. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2017 Salmonella strains* 
 
 
^For antimicrobial abbreviations: see List of Abbreviations page 1 
Marked in bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R, resistant/I, intermediate/ S, susceptible. 
*The result for the Salmonella strain WHO S-17.3 for chloramphenicol was omitted from evaluation (during the process of analyzing the WHO EQAS 2017 data, it 
was clear to the organizers that the database evaluation of the result related to the Salmonella strain WHO S-17.3 for chloramphenicol caused a large number of 
deviations. The expected result related to the testing of WHO S-17.3/chloramphenicol was 16/intermediate, only, due to the large number of deviations, the organizers 
decided not to evaluate the submitted results related to this strain/antimicrobial combination.) 
 
 
 
 
Strain Antimicrobial^ 
AMP CTX FOX CAZ CRO CHL CIP COL GEN MER NAL SMX TET TMP SXT 
WHO 
S-17.1 132/0/13 101/2/18 9/4/101 77/15/34 90/0/15 5/2/120 15/73/56 2/0/58 6/1/131 9/1/106 111/1/1 60/0/2 124/2/1 50/0/19 88/1/38 
WHO 
S-17.2 10/2/134 16/8/96 31/36/46 53/14/60 7/0/97 1/0/124 4/11/132 1/0/58 4/2/133 5/0/109 3/2/111 14/7/40 2/2/123 1/0/68 5/1/126 
WHO 
S-17.3 9/6/130 7/3/112 - 5/6/117 8/1/95 * 1/17/127 5/1/53 124/5/7 4/0/109 2/1/113 56/1/5 11/9/106 2/0/69 5/0/127 
WHO 
S-17.4 142/1/3 117/2/2 7/1/107 55/18/54 97/1/6 115/0/10 0/15/130 1/1/57 5/2/132 4/0/111 0/1/114 56/0/4 122/2/3 64/0/5 122/0/11 
WHO 
S-17.5 6/0/140 3/2/116 - 5/0/123 5/1/97 122/2/1 1/13/132 2/1/55 5/0/135 5/0/110 3/1/112 60/0/0 125/1/1 69/0/0 132/1/0 
WHO 
S-17.6 6/0/140 2/3/116 - 4/1/122 2/0/101 7/0/119 0/15/129 4/0/54 4/1/135 4/0/110 3/1/110 60/0/0 124/2/1 69/0/0 128/0/5 
WHO 
S-17.7 141/0/5 10/2/109 - 6/4/117 7/0/96 119/1/6 30/92/26 52/0/10 4/1/135 8/0/107 112/1/3 60/0/0 124/2/1 69/0/0 131/0/1 
WHO 
S-17.8 146/0/0 120/1/0 111/2/0 125/1/0 101/0/4 121/0/3 140/4/4 2/0/56 10/1/130 101/6/12 115/0/0 62/0/0 122/2/2 68/0/0 131/0/2 
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Table 9. Region-based categorization of EQAS participants’ performance of Salmonella AST 
 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test 
result 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2017 iteration 
A
fr
ic
a 
2001 7 80.1 9.6 7.7 2.5 10.2 19.8 
Cameroun, Egypt, 
Ghana, Kenya (2), 
Madagascar, Mauritius, 
Morocco, Nigeria (4), 
South Africa, Tanzania, 
United Republic of, The 
Gambia, Zambia, 
Zimbabwe 
2002 10 94.3 4.1 1.0 0.6 1.6 5.7 
2003 13 86.9 6.6 2.8 3.7 6.5 13.1 
2004 11 85.7 7.2 5.2 1.9 7.1 14.3 
2006 20 85.8 7.5 4.1 2.7 6.8 14.3 
2007 16 90.7 4.4 4.0 0.9 4.9 9.3 
2008 19 83.8 6.5 5.5 4.2 9.7 16.2 
2009 22 90.1 4.5 3.6 1.8 5.4 9.9 
2010 22 84.7 6.0 6.5 2.8 9.3 15.3 
2011 17 87.0 5.0 4.7 3.3 8.0 13.0 
2012 18 89.4 5.3 3.5 1.9 5.4 10.6 
2013 16 92.0 3.2 4.0 0.9 4.9 8.0 
2014 20 92.5 3.8 2.0 1.7 3.7 7.5 
2015 22 86.7 7.3 4.1 1.9 6.0 13.3 
2016 18 90.1 4.6 4.2 1.1 5.3 9.9 
2017 17 87.2 4.5 4.0 4.3 8.3 12.8 
C
en
tr
al
 A
sia
 &
 M
id
dl
e 
Ea
st
  
2001 10 87.7 6.3 5.2 0.8 6.0 12.3 
Bangladesh, India (4), 
Iran, Islamic rep. of (3), 
Israel, Nepal (6) 
2002 6 83.4 9.8 6.6 0.2 6.8 16.6 
2003 8 89.9 4.5 4.0 1.6 5.6 10.1 
2004 10 87.5 6.7 5.5 0.3 5.8 12.5 
2006 7 79.2 10.5 9.8 0.5 10.3 20.8 
2007 8 87.8 5.0 6.2 1.1 7.3 12.2 
2008 12 86.1 6.5 4.0 3.4 7.4 13.9 
2009 6 93.7 4.3 0.9 1.1 2.0 6.3 
2010 7 95.8 2.6 0.2 1.4 1.6 4.2 
2011 4 91.8 4.1 1.8 2.3 4.1 8.2 
2012 8 92.8 4.4 1.6 0.7 2.3 6.6 
2013 8 93.6 5.2 1.0 0.1 1.2 6.4 
2014 17 91.0 4.2 2.9 2.0 4.9 9.0 
2015 14 91.4 4.3 2.3 2.1 4.4 8.6 
2016 11 95.5 0.9 1.8 1.8 3.6 4.5 
2017 15 88.9 5.0 2.6 3.5 6.1 11.1 
C
ar
ib
be
an
  
2001 2 83.5 9.5 7.0 0.0 7.0 16.5 
Barbados, Cuba, 
Curaçao, Jamaica, 
Trinidad and Tobago 
2002 1 95.8 4.2 0.0 0.0 0.0 4.2 
2003 8 91.7 6.4 1.5 0.5 2.0 8.4 
2004 8 94.1 3.1 1.9 0.9 2.8 5.9 
2006 5 92.1 5.4 1.6 1.0 2.6 8.0 
2007 4 95.0 3.1 0.9 0.9 1.8 5.0 
2008 5 90.7 5.5 0.9 2.9 3.8 9.3 
2009 4 93.2 1.8 3.2 1.8 5.0 6.8 
2010 4 90.9 5.4 2.7 0.7 3.4 8.8 
2011 2 96.5 1.4 0.0 2.1 2.1 3.5 
2012 4 91.1 1.5 6.7 0.7 7.4 8.9 
2013 3 90.2 2.6 7.3 0.0 7.3 9.8 
2014 4 78.3 4.7 9.4 7.6 17.0 21.7 
2015 4 87.5 6.6 3.7 2.2 5.9 12.5 
2016 2 100.0 0.0 0.0 0.0 0.0 0.0 
2017 5 75.7 5.0 10.1 9.1 19.2 24.3 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella 
antimicrobial susceptibility testing 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2017 iteration 
Eu
ro
pe
 
8,5 
 
47 91.3 5.7 2.7 0.3 3.0 8.7 
Belgium, Croatia, 
Cyprus, Czech 
Republic, Denmark, 
Greece (3), Ireland, Italy 
(8), Kosova, 
Luxembourg (2), Malta, 
Poland (3), Portugal, 
Serbia (2), Slovak 
Republic, Slovenia, 
Spain, Turkey, Ukraine, 
United Kingdom 
2002 57 92.7 5.2 1.2 0.9 2.1 7.3 
2003 64 92.9 3.8 1.0 2.3 3.3 7.1 
2004 58 93.5 4.3 1.4 0.8 2.2 6.5 
2006 54 88.7 7.0 3.8 0.6 4.4 11.3 
2007 49 94.2 3.7 1.6 0.4 2.0 5.7 
2008 51 91.2 4.4 2.5 1.9 4.4 8.8 
2009 40 95.1 2.6 1.3 0.9 2.2 4.8 
2010 39 92.4 4.1 1.2 2.3 3.5 7.6 
2011 36 92.5 4.5 1.7 1.3 3.0 7.5 
2012 40 95.5 2.8 1.2 0.4 1.7 4.5 
2013 37 95.7 2.5 1.4 0.3 1.7 4.2 
2014 40 96.6 2.1 0.8 0.5 1.3 3.4 
2015 38 93.4 4.1 1.3 1.2 2.5 6.6 
2016 36 96.9 1.5 1.2 0.5 1.6 3.1 
2017 33 92.8 2.4 2.1 2.7 4.8 7.2 
N
or
th
 A
m
er
ic
a 
 
2001 4 95.8 3.8 0.0 0.4 0.4 4.2 
Canada (5), United States 
of America (4) 
2002 3 90.5 6.9 0.6 2.0 2.6 9.5 
2003 7 93.4 5.2 0.0 1.4 1.4 6.6 
2004 9 94.2 4.2 1.8 0.0 1.8 6.0 
2006 8 94.8 2.9 1.0 1.3 2.3 5.2 
2007 10 95.4 2.9 0.8 0.8 1.6 4.6 
2008 14 96.4 0.6 0.4 2.6 3.0 3.6 
2009 10 98.7 0.0 0.4 0.9 1.3 1.3 
2010 11 94.8 2.6 0.2 2.4 2.6 5.2 
2011 9 92.1 2.6 1.5 3.8 5.3 7.9 
2012 10 96.0 2.1 1.0 0.9 1.9 4.0 
2013 7 98.4 1.3 0.0 0.2 0.2 1.6 
2014 8 96.9 2.2 0.4 0.6 0.9 3.1 
2015 8 94.5 2.0 0.8 2.8 3.6 5.5 
2016 8 99.1 0.2 0.0 0.7 0.7 0.9 
2017 9 97.1 1.2 0.6 1.2 1.7 2.9 
O
ce
an
ia
  
2001 6 91.8 4.7 2.7 0.9 3.6 8.2 
Australia, New Zealand 
2002 7 91.7 6.2 0.0 2.0 2.0 8.3 
2003 9 94.3 2.5 1.2 2.0 3.2 5.7 
2004 11 97.1 2.5 0.3 0.1 0.4 2.9 
2006 7 93.4 4.6 0.9 1.1 2.0 6.6 
2007 1 98.9 1.1 0.0 0.0 0.0 1.1 
2008 4 93.9 3.8 0.0 2.3 2.3 6.1 
2009 4 95.9 3.2 0.3 0.6 0.9 4.1 
2010 4 92.5 4.6 0.6 2.3 2.9 7.5 
2011 4 93.8 5.6 0.6 0.0 0.6 6.2 
2012 4 95.5 3.1 0.6 0.9 1.4 4.5 
2013 4 96.8 2.9 0.0 0.3 0.3 3.2 
2014 5 97.4 2.0 0.0 0.6 0.6 2.6 
2015 5 95.3 3.8 0.5 0.5 1.0 4.8 
2016 3 98.1 0.0 0.5 1.4 1.9 1.9 
2017 2 96.1 2.6 0.0 1.3 1.3 3.9 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial 
susceptibility testing. 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2017 iteration 
R
us
sia
 
2001 1 81.9 15.3 2.8 0.0 2.8 18.1 
- none -  
2002 1 84.5 9.9 5.6 0.0 5.6 15.5 
2003 1 100.0 0.0 0.0 0.0 0.0 0.0 
2004 4 91.2 6.6 1.5 0.7 2.2 8.8 
2006 5 87.4 8.2 2.7 1.7 4.4 12.6 
2007 8 88.9 5.8 4.8 0.4 5.2 11.0 
2008 6 92.2 4.7 1.4 1.7 3.1 7.8 
2009 6 93.8 2.1 3.3 0.8 4.1 6.2 
2010 8 94.3 3.3 1.3 1.1 2.4 5.7 
2011 7 90.0 4.8 3.2 2.0 5.2 10.0 
2012 6 97.4 2.0 0.0 0.6 0.6 2.6 
2013 2 98.2 1.8 0.0 0.0 0.0 1.8 
2014 4 98.2 0.3 0.9 0.6 1.5 1.8 
2015 4 98.7 1.0 0.0 0.3 0.3 1.3 
2016 - - - - - - - 
2017 - - - - - - - 
La
tin
 A
m
er
ic
a 
 
 
2001 11 90.8 6.9 1.4 1.0 2.4 9.2 
Argentina, Belize, Bolivia, 
Brazil (2), Chile, Colombia 
(3), Costa Rica (2), 
Ecuador, Guatemala (2), 
Honduras, Mexico (2), 
Panama (2), Paraguay, 
Peru, Suriname, Uruguay, 
Venezuela 
2002 13 93.7 4.6 0.7 1.0 1.7 6.3 
2003 12 90.8 4.2 2.0 3.0 5.0 9.2 
2004 17 94.4 4.7 0.8 0.1 0.9 5.6 
2006 16 88.7 6.3 4.5 0.6 5.1 11.3 
2007 17 94.9 1.8 1.9 1.4 3.3 5.0 
2008 20 93.0 3.4 1.5 2.1 3.6 7.0 
2009 20 95.6 2.1 1.1 1.2 2.3 4.4 
2010 23 90.8 2.1 5.6 1.4 7.1 9.2 
2011 22 90.8 2.8 3.1 3.3 6.4 9.2 
2012 25 94.4 1.6 3.0 1.0 4.0 5.6 
2013 25 95.5 2.6 1.2 0.3 1.5 4.2 
2014 24 96.5 1.9 1.1 0.6 1.7 3.5 
2015 20 94.9 3.8 0.6 0.7 1.3 5.1 
2016 24 95.6 2.5 1.4 0.5 1.9 4.4 
2017 24 91.1 3.3 2.3 3.2 5.5 8.9 
C
hi
na
 
 
2001 4 98.9 0.8 0.0 0.3 0.3 1.1 
China (14) 
2002 3 96.0 4.0 0.0 0.0 0.0 4.0 
2003 8 90.1 3.6 2.8 3.6 6.4 10.0 
2004 8 96.0 3.2 0.7 0.1 0.8 4.0 
2006 6 89.6 7.0 2.9 0.5 3.4 10.4 
2007 10 98.3 1.1 0.3 0.2 0.5 1.6 
2008 18 92.8 3.7 0.8 2.7 3.5 7.2 
2009 14 94.8 2.2 2.1 0.8 2.9 5.1 
2010 9 92.1 4.5 1.6 1.8 3.4 7.9 
2012 9 95.3 3.0 0.5 1.2 1.6 4.7 
2013 8 96.9 2.0 0.5 0.5 1.0 3.1 
2014 8 97.0 1.2 0.1 1.6 1.8 3.0 
2015 15 92.8 2.0 4.0 1.1 5.1 7.2 
2016 16 96.7 0.4 1.8 1.1 2.9 3.3 
2017 14 93.4 2.9 0.7 3.0 3.7 6.6 
^S. susceptible; I. intermediate; R. resistant 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial 
susceptibility testing.  
 
^S. susceptible; I. intermediate; R. resistant 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2017 iteration 
So
ut
he
as
t A
sia
  
2001 16 88.1 7.7 2.3 1.9 4.2 11.9 
Cambodia, Japan (2), 
Korea, Rep of (2), LAO 
PDR, Malaysia (5), 
Philippines (2), Singapore, 
Sri Lanka (2), Taiwan, 
Thailand (13), Viet Nam 
2002 18 89.0 8.1 1.4 1.6 3.0 11.0 
2003 17 87.4 5.2 4.7 2.7 7.4 12.6 
2004 16 92.8 4.4 2.3 0.5 2.8 7.2 
2006 15 90.0 8.1 1.2 0.8 2.0 10.0 
2007 20 93.9 4.0 1.4 0.7 2.1 6.1 
2008 19 90.5 4.7 2.2 2.6 4.8 9.5 
2009 27 91.8 4.1 3.0 1.2 4.2 8.3 
2010 25 92.8 3.8 1.5 1.9 3.4 7.2 
2011 26 90.5 3.5 2.4 3.5 5.9 9.5 
2012 35 91.7 3.9 3.5 0.9 4.4 8.3 
2013 35 93.4 3.2 2.5 0.7 3.2 6.4 
2014 8 97.0 1.2 0.1 1.6 1.8 3.0 
2015 25 89.9 6.0 2.6 1.5 4.1 10.1 
2016 30 93.5 2.2 3.5 0.8 4.3 6.5 
2017 31 91.9 2.9 2.1 3.2 5.2 8.1 
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Table 10. EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
  
 Method Perfor-mance4.5 AMP CAZ CHL CIP COL CRO CTX 
FIS 
(SMX)2 FOX GEN MER NAL STR SXT TET TMP 
Accepted 
interval1 
MIC (μg/ml)    2-8 0.06-0.5 2-8 0.004-0.016 0.25-2 0.03-0.12 0.03-0.12 8-32 2-8 0.25-1 0.008-0.06 1-4 4-163 ≤0.5/9.5 0.5-2 0.5-2 
Disks (mm)   15-22 25-32 21-27 30-40 - 29-35 29-35 15-23 23-29 19-26 28-34 22-28 12-20 23-29 18-25 21-28 
EQ
A
S 
ite
ra
tio
n 
(to
ta
l n
o.
 o
f p
ar
tic
ip
an
ts)
 
2000  
(44) MIC & Disk 
No.4 37 - 38 35 - - - 19 - 39 - 37 36 - 42 31 
%5 27 - 37 20 - - - 53 - 23 - 35 22 - 42 30 
2001 
(107) MIC & Disk 
No.4 97 - 97 97 - - - 53 - 99 - 74 81 90 96 50 
%5 19 - 20 14 - - - 34 - 12 - 14 12 14 22 22 
2002 
(114) MIC & Disk 
No.4 109 - 107 108 - - - 57 - 108 - 102 82 102 102 66 
%5 16 - 15 14 - - - 26 - 12 - 14 11 12 13 11 
2003 
(144) MIC & Disk 
No.4 140 - 137 138 - - - 82 - 138 - 132 105 129 137 79 
%5 14 - 22 9 - - - 17 - 9 - 16 9 14 19 14 
2004 
(140) MIC & Disk 
No.4 132 - 128 132 - - 111 84 - 134 - 126 110 120 129 87 
%5 10 - 13 8 - - 18 16 - 10 - 9 6 11 13 9 
2006 
(137) MIC & Disk 
No.4 133 96 126 127 - - 115 74 - 131 - 122 106 122 125 74 
%5 14 15 18 8 - - 21 29 - 14 - 20 11 19 12 17 
2007 
(126) MIC & Disk 
No.4 124 92 123 121 - - 104 64 - 124 - 120 97 107 117 67 
%5 11 9 14 12 - - 16 22 - 6 - 7 6 13 7 10 
2008 
(147) 
MIC & Disk No.
4 147 111 135 144 - - 124 71 - 145 - 136 101 129 139 79 
%5 12 9 10 8 - - 14 14 - 8 - 8 12 13 7 13 
MIC No.
4 33 23 24 33 - - 23 18 - 31 - 23 19 22 28 16 
%5 0 5 0 6 - - 9 11 - 0 - 0 11 9 0 13 
Disk No.
4 114 89 112 111 - - 101 53 - 114 - 113 82 107 111 63 
%5 16 10 12 8 - - 15 15 - 11 - 10 12 14 9 13 
2009 
(129) 
MIC & Disk No.
4 128 100 121 124 - 88 107 63 - 123 - 117 98 113 122 70 
%5 16 13 15 7 - 16 10 11 - 18 - 13 10 14 14 11 
MIC (27) No.
4 27 19 24 26 - 20 20 14 - 25 - 24 19 21 27 25 
%5 11 11 8 8 - 15 15 21 - 12 - 8 5 19 11 13 
Disk (102) No.
4 101 81 97 98 - 68 87 49 - 98 - 93 79 92 95 55 
%5 16 14 16 6 - 16 9 10 - 18 - 14 11 12 15 11 
2010 
(116) 
MIC & Disk No.
4 114 97 108 115 - 79 100 51 - 112 - 104 84 101 110 63 
%5 11 9 9 6 - 10 14 11 - 11 - 5 5 12 5 15 
MIC (24) No.
4 25 15 21 25 - 15 17 12 - 24 - 19 17 17 24 11 
%5 12 20 10 8 - 7 18 8 - 13 - 16 18 18 17 36 
Disk (91) No.
4 89 82 87 90 - 64 83 39 - 88 - 85 67 84 86 52 
%5 9 6 8 4 - 9 11 10 - 9 - 2 1 10 1 8 
2011 
(112) 
MIC & Disk No.
4 111 89 102 109 - 76 96 50 - 103 - 103 72 99 107 51 
%5 17 4 11 7 - 7 9 8 - 11 - 8 4 16 7 14 
MIC (23) No.
4 23 15 18 22 - 16 15 13 - 22 - 19 17 16 21 11 
%5 4 7 0 9 - 6 0 8 - 9 - 0 6 6 5 0 
Disk (89) No.
4 88 74 84 87 - 60 81 37 - 81 - 84 55 83 86 40 
%5 20 4 13 7 - 7 11 8 - 11 - 10 4 18 8 18 
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Table 10 (continued). EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
 Method Perfor-mance4.5 AMP CAZ CHL CIP COL CRO CTX 
FIS 
(SMX)2 FOX GEN MER NAL STR SXT TET TMP 
Accepted 
interval1 
MIC (μg/ml)    2-8 0.06-0.5 2-8 0.004-0.016 0.25-2 0.03-0.12 0.03-0.12 8-32 2-8 0.25-1 0.008-0.06 1-4 4-163 ≤0.5/9.5 0.5-2 0.5-2 
Disks (mm)   15-22 25-32 21-27 30-40 - 29-35 29-35 15-23 23-29 19-26 28-34 22-28 12-20 23-29 18-25 21-28 
EQ
A
S 
ite
ra
tio
n 
(to
ta
l n
o.
 o
f p
ar
tic
ip
an
ts)
 
2012 
(135) 
MIC & Disk No.
4 134 111 121 131 - 90 115 53 - 127 - 121 89 112 129 66 
%5 13 12 7 6 - 11 10 11 - 9 - 9 8 13 10 21 
MIC (37) No.
4 37 26 31 35 - 23 28 19 - 35 - 31 26 23 35 22 
%5 3 4 0 3 - 0 4 5 - 3 - 3 8 0 0 9 
Disk (98) No.
4 97 85 90 96 - 67 87 34 - 92 - 90 63 89 94 44 
%5 16 14 9 7 - 15 11 15 - 11 - 11 8 16 14 27 
2013 
(122) 
MIC & Disk No.
4 117 100 112 119 - 82 107 44 - 113 - 113 - 101 114 59 
%5 12 7 5 7 - 4 8 10 - 6 - 11 - 8 8 11 
MIC (33) No.
4 31 25 28 32 - 19 27 17 - 32 - 28 - 22 32 22 
%5 6 4 4 13 - 5 11 18 - 9 - 11 - 5 6 5 
Disk (89) No.
4 86 75 84 87 - 63 80 27 - 81 - 85 - 79 82 37 
%5 13 8 6 5 - 5 6 7 - 4 - 9 - 10 7 8 
2014 
(115) 
MIC & Disk No.
4 111 99 101 108 - 75 97 49 - 111 - 103 - 102 104 50 
%5 5 7 7 6 - 7 14 14 - 8 - 8 - 8 7 2 
MIC (28) No.
4 27 21 24 27 - 16 22 16 - 28 - 24 - 21 25 12 
%5 4 5 4 15 - 6 14 0 - 14 - 8 - 14 0 0 
Disk (87) No.
4 84 78 77 81 - 59 75 33 - 83 - 79 - 81 79 38 
%5 6 8 8 4 - 7 15 21 - 6 - 8 - 6 9 3 
2015 
(117) 
MIC&Disk No.
4 113 101 101 112 - 78 99 54 75 112 74 100  - 104 106 57 
%5 8 5 7 7 - 9 6 11 9 9 12 7  - 13 8 9 
MIC (31) No.
4 30 26 25 30 - 16 25 15 20 30 19 24  - 24 27 16 
%5 3 8 4 13 - 0 12 7 10 7 11 4  - 8 7 13 
Disk (85) No.
4 83 75 76 82 - 62 74 39 55 82 55 76  - 80 79 41 
%5 10 4 8 5 - 11 4 13 9 10 13 8  - 14 8 7 
2016 
(106) 
MIC&Disk No.
4 101 93 95 101 - 76 94 54 84 99 88 91 - 91 97 59 
%5 11 5 13 9 - 16 15 24 7 8 10 9 - 8 10 14 
MIC (30) No.
4 27 24 24 27 - 17 24 13 22 29 25 20 - 20 25 16 
%5 4 4 0 7 - 12 4 23 0 3 4 0 - 0 8 13 
Disk (76) No.
4 74 69 71 74 - 59 70 41 62 70 63 71 - 71 72 43 
%5 14 6 17 9 - 17 19 24 10 10 13 11 - 10 11 14 
2017 
(115) 
MIC&Disk No.
4 114 101 103 113 56 82 93 56 92 107 93 89 - 95 99 61 
%5 13 11 10 10 20 16 14 27 10 7 10 7 - 6 10 8 
MIC (41) No.
4 41 33 35 41 28 25 31 24 30 38 34 31 - 29 34 26 
%5 5 6 0 7 4 12 6 17 3 5 6 3 - 0 6 0 
Disk (74) No.
4 73 68 68 72 28 57 62 32 62 69 59 58 - 66 65 35 
%5 18 13 15 11 36 18 18 34 13 7 12 9 - 9 12 14 
0For antimicrobial abbreviations: see List of Abbreviations page 1 
1CLSI standard. Performance Standards for Antimicrobial Disk and Dilution Susceptibility testing. 22nd Informational supplement. CLSI document M100-S22. 2012 Wayne. PA. USA 
2FIS (sulfisoxazole) covers the group of SMX (sulfonamides); 3Quality control range developed by the manufacturer of Sensititre; 4No.. number of laboratories performing the analysis; 5%. percentage of laboratories reporting 
erroneous results; -. not determined 
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Table 11. Proportion of laboratories that obtained the expected result. Number (n/N) and 
percentages of laboratories which correctly detected and confirmed the ESBL-producing 
Salmonella strains. 
 
Isolate no. Expected interpretation Confirmatory tests 
WHO 2017 S-17.1 Presumptive ESBL-phenotype 80/92 (87%) 
WHO 2017 S-17.2 Presumptive AmpC-phenotype 26/77 (34%) 
WHO 2017 S-17.3  -   - 
WHO 2017 S-17.4 Presumptive ESBL-phenotype 82/91 (90%) 
WHO 2017 S-17.5   -   - 
WHO 2017 S-17.6   -   - 
WHO 2017 S-17.7   -   - 
WHO 2017 S-17.8 Presumptive carbapenemase-phenotype 62/94 (66%) 
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SIGN-UP FOR EQAS 2017 
Greetings to the WHO Global Foodborne Infections Network (WHO GFN) Members: 
WHO GFN strives to increase the quality of laboratory-based surveillance of Salmonella by 
encouraging national and regional reference laboratories that attended WHO GFN training courses 
to participate in the External Quality Assurance System (EQAS). We are pleased to announce the 
launch of the 2017 EQAS cycle. 
 
WHY PARTICIPATE IN EQAS? 
EQAS provides the opportunity for proficiency testing which is considered an important tool for the 
production of reliable laboratory results of consistently good quality. 
 
WHAT IS OFFERED IN EQAS? 
This year, WHO EQAS offers the following components:  
- Serogrouping, serotyping and antimicrobial susceptibility testing of eight Salmonella isolates. 
 
WHO SHOULD PARTICIPATE IN EQAS 2017? 
All national and regional reference laboratories which perform analysis on Salmonella and are 
interested in participating in an external quality assurance program are invited to participate. 
We expect that all national and regional reference laboratories that attended WHO GFN Training 
Courses will participate in the EQAS.  
The WHO GFN Regional Centers in cooperation with the EQAS Coordinator will evaluate the list 
of laboratories that sign up for EQAS 2017. Laboratories which signed up and received bacterial 
isolates in year 2016 but did not submit any result should provide a consistent explanation for this if 
they want to participate in 2017.  
 
COST FOR PARTICIPATING IN EQAS 
There is no participation fee. Laboratories should, however, cover the expenses for parcel shipment 
if they can afford it. If FedEx has ‘Dangerous Goods-service’ in your country or if you have a 
DHL-account no, please provide your FedEx or DHL import account number (for import of 
UN3373 Biological Substance Category B) in the sign-up form or, alternatively, to the EQAS 
Coordinator (please find contact information below). We need this information at this stage to save 
time and resources. Participating laboratories are responsible for paying any expenses related to 
taxes or custom fees applied by their country.  
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HOW TO SIGN- UP FOR EQAS 2017 
This link will open a sign-up webpage: http://eqas.food.dtu.dk/who/signup  
In this webpage, you will be asked to provide the following information: 
-       Name of institute, department, laboratory, and contact person 
-       Complete mailing address for shipment of bacterial isolates (no post-office box number) 
-       Telephone and fax number, e-mail address 
-       FedEx or DHL import account number (if available) 
-       Approximate number of Salmonella isolates annually serogrouped/serotyped 
-       Approximate number of Salmonella isolates annually tested for antimicrobial susceptibility 
-       Availability of ATCC 25922 E. coli reference strain 
-       Components of EQAS 2017 you plan to participate in 
-       Level of reference function in your country  
 
If you experience any problem in the sign-up webpage, please try again a few days later. If 
problems persist, please contact the EQAS Coordinator Susanne Karlsmose Pedersen: E-mail 
suska@food.dtu.dk.  
 
TIMELINE FOR SHIPMENT OF ISOLATES AND AVAILABILITY OF PROTOCOLS 
A number of different institutions will ship the bacterial isolates, and you will receive information 
concerning the institution shipping your parcel. The bacterial isolates will be shipped in October 
2017. 
In order to minimize delays, please send a valid import permit to the EQAS coordinator. Please 
apply for a permit to receive the following: “UN3373, Biological Substance Category B”: eight 
Salmonella strains, and (for new participants performing antimicrobial susceptibility testing on 
Salmonella) one Escherichia coli reference strain. 
Protocols and all relevant information will be available for download from the website 
http://www.antimicrobialresistance.dk/233-169-215-eqas.htm. 
 
DEADLINE FOR SUBMITTING RESULTS TO THE NATIONAL FOOD INSTITUTE 
Results must be submitted to the National Food Institute (DTU Food) by 28th February 2018 
through the password-protected website. An evaluation report will be generated upon submission of 
results. Full anonymity is ensured, and only DTU Food and the WHO GFN Regional Centre in your 
region will have access to your results. 
Deadline for sign-up for the WHO GFN EQAS 2017 is August 4th, 2017 
 
---   ---   --- 
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Synergy Synergy
CTX:/CTX:Cl CAZ:/CAZ:Cl
WHO 2017 S-17.1 Salmonella Infantis I 6,7:r:1,5 ESBL >64 RESIST >64 RESIST synergy 4 SUSC 16 RESIST synergy >32 RESIST <=8 SUSC 0.25 INTER
WHO 2017 S-17.2 Salmonella  Havana I 13,23:f,g:- AmpC <=1 SUSC 1 SUSC no synergy 32 RESIST 4 RESIST no synergy 0.12 SUSC <=8 SUSC 0.06 SUSC
WHO 2017 S-17.3 Salmonella  Enteritidis I 9,12:g,m;- - 4 SUSC 0.5 SUSC 1 SUSC 0.25 SUSC 16 INTER 0.06 SUSC
WHO 2017 S-17.4 Salmonella  Rissen I 6,7:f,g:- ESBL >64 RESIST 32 RESIST synergy 8 SUSC 2 RESIST synergy 64 RESIST >128 RESIST 0.03 SUSC
WHO 2017 S-17.5 Salmonella  Weltevreden I 3,10:r;z6 - <=1 SUSC <=0.25 SUSC <=0.5 SUSC 0.03 SUSC 128 RESIST 0.03 SUSC
WHO 2017 S-17.6 Salmonella  Schwarzengrund I 4,12:d:1,7 - 2 SUSC <=0.25 SUSC <=0.5 SUSC 0.06 SUSC <=8 SUSC 0.03 SUSC
WHO 2017 S-17.7 Salmonella  Typhimurium I 4,5,12:i:1,2 - >64 RESIST 0.5 SUSC <=0.5 SUSC 0.12 SUSC 64 RESIST 0.5 INTER
WHO 2017 S-17.8 Salmonella  Kentucky I 8,20:i:z6 Carbapenemase >64 RESIST >64 RESIST no synergy 64 RESIST >128 RESIST no synergy >256 RESIST >128 RESIST 8 RESIST
WHO 2017 S-17.1 Salmonella Infantis I 6,7:r:1,5 ESBL <=1 SUSC <=0.5 SUSC 0.06 SUSC >128 RESIST >1024 RESIST >64 RESIST >32 RESIST >4 RESIST
WHO 2017 S-17.2 Salmonella  Havana I 13,23:f,g:- AmpC <=1 SUSC <=0.5 SUSC 0.06 SUSC <=4 SUSC 64 SUSC 4 SUSC 0.5 SUSC 0.12 SUSC
WHO 2017 S-17.3 Salmonella  Enteritidis I 9,12:g,m;- - 2 SUSC 32 RESIST 0.06 SUSC 8 SUSC >1024 RESIST 4 SUSC <=0.25 SUSC 0.12 SUSC
WHO 2017 S-17.4 Salmonella  Rissen I 6,7:f,g:- ESBL <=1 SUSC 1 SUSC 0.06 SUSC <=4 SUSC >1024 RESIST >64 RESIST >32 RESIST >32 RESIST
WHO 2017 S-17.5 Salmonella  Weltevreden I 3,10:r;z6 - <=1 SUSC <=0.5 SUSC 0.06 SUSC <=4 SUSC >1024 RESIST >64 RESIST >32 RESIST >32 RESIST
WHO 2017 S-17.6 Salmonella  Schwarzengrund I 4,12:d:1,7 - 2 SUSC <=0.5 SUSC 0.06 SUSC 8 SUSC >1024 RESIST >64 RESIST >32 RESIST >32 RESIST
WHO 2017 S-17.7 Salmonella  Typhimurium I 4,5,12:i:1,2 - 8 RESIST <=0.5 SUSC 0.06 SUSC >128 RESIST >1024 RESIST >64 RESIST >32 RESIST >32 RESIST
WHO 2017 S-17.8 Salmonella  Kentucky I 8,20:i:z6 Carbapenemase <=1 SUSC 1 SUSC 1 RESIST >128 RESIST >1024 RESIST >64 RESIST >32 RESIST >32 RESIST
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3.1  Shipping, receipt and storage of strains  ....................................................................... 2 
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1 INTRODUCTION 
In 2000, the Global Foodborne Infections Network (formerly known as WHO Global Salm-Surv) 
launched an External Quality Assurance System (EQAS). The EQAS is organized by the National 
Food Institute, Technical University of Denmark (DTU Food), in collaboration with partners and 
Regional Sites in WHO GFN.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs, it is placed with a competent subcontractor and the National Food Institute is 
responsible for the subcontractor’s work. 
The WHO EQAS 2017 includes serotyping and antimicrobial susceptibility testing of eight 
Salmonella strains and antimicrobial susceptibility testing of the Escherichia coli ATCC 25922 
(CCM 3954) reference strain for quality control (QC).  
The above-mentioned QC reference strain is included in the parcel only for new participants of the 
EQAS who did not receive it previously. The QC reference strain supplied is an original 
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CERTIFIED culture provided free of charge, and should be used for future internal quality control 
for antimicrobial susceptibility testing in your laboratory. The QC reference strain will not be 
included in the years to come. Therefore, please take proper care of these strains. Handle and 
maintain them as suggested in the manual ‘Subculture and Maintenance of QC Strains’ available on 
the WHO Collaborating Centre website (see www.antimicrobialresistance.dk). 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of serotyping and antimicrobial susceptibility testing of enteric human pathogens, especially 
Salmonella. A further objective is to assess and improve the comparability of surveillance data on 
Salmonella serotypes and antimicrobial susceptibility reported by different laboratories. Therefore, 
the laboratory work for this EQAS should be done by using the methods routinely used in your 
laboratory. 
3 OUTLINE OF THE EQAS 2017 
3.1 Shipping, receipt and storage of strains 
In October 2017 around 200 laboratories located worldwide will receive a parcel containing eight 
Salmonella strains. An E. coli ATCC 25922 reference strain will be included for participants who 
signed up to perform antimicrobial susceptibility testing (AST) and did not receive it previously. 
All provided strains belong to UN3373, Biological substance category B. Extended Spectrum Beta 
Lactamase (ESBL)-, AmpC- or carbapenemase-producing strains could be included in the selected 
material.  
 Please confirm receipt of the parcel through the confirmation form enclosed in the shipment. 
The Salmonella strains are shipped as agar stab cultures whereas the reference strain is shipped 
lyophilised. On arrival, the agar stab culture must be stored in a dark place at 2⁰C to 8⁰C. If 
receiving a lyophilized reference culture, store in a dark, cool place. The agar stab cultures must be 
sub-cultured and prepared for storage in your strain collection (e.g. in a -80°C freezer). This set of 
cultures should serve as reference if discrepancies are detected during the testing (e.g. they can be 
used to detect errors such as mis-labelling or contamination). 
3.2 Serotyping of Salmonella  
The eight Salmonella strains should be serotyped by using the method routinely used in the 
laboratory. Also serogroup results will be evaluated, therefore, if you do not have all the necessary 
antisera for a serotyping, please go as far as you can in the identification and report the serogroup. 
Serogroups should be reported using terms according to Kauffmann-White-Le Minor (Grimont and 
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Weill, 2007. 9th ed. Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for 
Reference and Research on Salmonella). 
Please fill in information concerning the brand of antisera used for typing in the fields available in 
the database for entering results. In addition, we kindly ask you to report which antisera you think 
are required to complete the serotyping, if relevant. 
3.3 Antimicrobial susceptibility testing of Salmonella strains and Escherichia coli ATCC 
25922  
The Salmonella strains as well as the E. coli ATCC 25922 reference strain should be tested for 
susceptibility towards as many as possible of the antimicrobials mentioned in the test form. Please 
use the methods routinely used in your laboratory.  
For reconstitution of the E. coli reference strain, please see the document ‘Instructions for opening 
and reviving lyophilised cultures’ on the WHO Collaborating Centre website (see 
www.antimicrobialresistance.dk). 
Testing of gentamicin susceptibility may be valuable for monitoring purposes. Therefore we kindly 
ask you to disregard, for the purpose of this proficiency trial, that the Clinical and Laboratory 
Standards Institute (CLSI) guidelines state that Salmonella should not be reported as susceptible to 
aminoglycosides. 
The breakpoints used in this EQAS for interpreting MIC results are in accordance with CLSI values 
(Table 1). Consequently, interpretation of MIC results will lead to categorization of strains into 
three categories: resistant (R), intermediate (I) and susceptible (S). In the evaluation report you 
receive upon result submission, you can find that obtained interpretations in accordance with the 
expected interpretation will be defined as ‘correct’, whereas deviations from the expected 
interpretation will be defined as ‘minor’ (I  S or I  R), ‘major’ (S interpreted as R) or ‘very 
major’ (R interpreted as S).  
Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results in the fields available in the database (or in the test forms). 
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Table 1. Interpretive breakpoint for Salmonella antimicrobial susceptibility testing 
Antimicrobials  Reference value, MIC (g/mL) Reference value, Disk diffusion (mm) 
Susceptible Intermediate Resistant Resistant Intermediate Susceptible 
Ampicillin, AMP 8 16 32 13 14-16 17 
Cefotaxime, CTX* ≤1 - >1 27 - >27
Cefoxitin, FOX 8 16 32 14 15-17 18 
Ceftazidime, CAZ* ≤1 - >1 22 - >22
Ceftriaxone, CRO* ≤1 - >1 25 - >25
Chloramphenicol, CHL 8 16 32 12 13-17 18 
Ciprofloxacin, CIP 0.06 0.12-0.5 1 
20mm 
(5µg) 
or 
<23mm 
(1µg)** 
21-30mm
(5µg)
or
(1µg)**
31mm (5µg) 
or 
23mm 
(1µg)** 
Colistin, COL*** ≤2 - 4 Not 
applicable 
Not 
applicable 
Not 
applicable 
Gentamicin, GEN 4 8 16 12 13-14 15 
Meropenem, MER* ≤0.12 - >0.12 <27 - 27 
Nalidixic acid, NAL 16 - 32 13 14-18 19 
Sulfonamides, SMX 256 - 512 12 13-16 17 
Tetracycline, TET 4 8 16 11 12-14 15 
Trimethoprim, TMP 8 - 16 10 11-15 16 
Trimethoprim + 
sulfamethoxazole, 
TMP+SMX, SXT 
2/38 - 4/76 10 11-15 16 
Reference values used in this EQAS are according to CLSI (M100, 27th edition), with the following exceptions: 
* For the cephalosporins and meropenem, the application of the interpretative criteria is intended to indicate if the
microorganism is a presumptive ESBL- or carbapenemase-producer. Reference values for the cephalosporins are
according to CLSI M100 Table 3A. These interpretative criteria are also applied for Salmonella test strains for
interpretation of AST results in this EQAS. Reference values for meropenem are based on epidemiological cut off
values from www.eucast.org.
** The publication by Cavaco LM and Aarestrup FM (J. Clin. Microbiol. 2009. Sep;47(9):2751-8) provides the
background for these interpretative criteria in the WHO GFN EQAS.
*** Reference values for colistin are based on CLSI M100 Table 2A-2. In the current EQAS these values should be
applied for the interpretation of Salmonella AST results into the category as susceptible or resistant.
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Concerning ciprofloxacin susceptibility tests, the applied breakpoints take into consideration 
mechanisms of resistance due to plasmid-mediated quinolone resistance genes (e.g. qnr-genes) and 
one-point-mutation in the gyrase gene. 
Important notes: beta-lactam resistance 
The following tests for detection of ESBL-, AmpC-, and carbapenamase-producing phenotypes are 
optional in relation to the current WHO GFN EQAS.  
If choosing to participate in this component of the EQAS, all strains displaying reduced 
susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) should be tested 
for ESBL-, AmpC, or carbapenemase-production by confirmatory tests. Reduced susceptibility to 
any of the above-mentioned antimicrobials indicates that the bacterial strain is an ESBL-, AmpC, or 
carbapenemase-producing phenotype. 
Confirmatory test for ESBL production requires the use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone, and in combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) by microbroth dilution methods or E-test; a ≥ 3 twofold concentration decrease in an 
MIC for either antimicrobial agent tested in combination with clavulanic acid vs. its MIC when 
tested alone (E-test 3 dilution steps difference; MIC CTX : CTX/Cl or CAZ : CAZ/Cl ratio  8) or 
ii) by disk diffusion; a  5 mm increase in a zone diameter for either antimicrobial agent tested in
combination with clavulanic acid vs. its zone when tested alone (CLSI M100 Table 2A;
Enterobacteriaceae). The presence of synergy indicates ESBL production.
Detection of AmpC-type beta-lactamases can be performed by testing the bacterial culture for 
susceptibility to cefoxitin (FOX). Resistance to FOX indicates the presence of an AmpC-type beta-
lactamase.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MER). 
Reduced susceptibility to MER indicates that the bacterial strain is a carbapenemase-producer. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (available in The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2015, EFSA Journal 
2017;15(2):4694,212 pp (page 43).  
The following summary of these recommendations indicate how the phenotypes should be 
categorized: 
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ESBL-phenotype: 
- CTX or CAZ > 1 mg/L AND 
- MER ≤ 0.12 mg/L AND 
- FOX ≤ 8 mg/L AND 
- Synergy for CTX : CTX/Cl and/or CAZ : CAZ/Cl 
ESBL+AmpC-phenotype: 
- CTX or CAZ > 1 mg/L AND 
- MER ≤ 0.12 mg/L AND 
- FOX > 8 mg/L AND 
- Synergy for CTX : CTX/Cl and/or CAZ : CAZ/Cl 
AmpC-phenotype: 
- CTX or CAZ > 1 mg/L AND 
- MER ≤ 0.12 mg/L AND 
- FOX > 8 mg/L AND 
- No synergy for CTX : CTX/Cl nor CAZ : CAZ/Cl 
(note, presence of ESBLs is not excluded) 
Carbapenemase-phenotype: 
- MER > 0.12 mg/L 
(note, presence of ESBLs or AmpCs is not excluded) 
Other-phenotype: 
- Not covered by any of the above categories AND 
- CTX, CAZ, FOX, or MER > interpretative criteria as susceptible in Table 1 (i.e. exhibits 
reduced susceptibility) 
No ESBL-, AmpC-, or carbapenemase: 
- CTX, CAZ, FOX, and MER ≤ interpretative criteria as susceptible in Table 1 (i.e. exhibits 
susceptibility) 
 
The genotype obtained by PCR and/or sequencing may be necessary to correctly categorize a 
bacterial test strain as either of the categories, ESBL-, AmpC, and/or carbapenemase-producer, but 
is not requested as part of this WHO GFN EQAS.  
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4 REPORTING OF RESULTS AND EVALUATION 
We recommend that you write your results in the enclosed test forms and that you read carefully the 
description in paragraph 5 before entering your results in the web database. For entering your 
results via the web, you will be guided through all steps on the screen and you will immediately be 
able to view and print a report evaluating your results. Results in agreement with the expected 
interpretation are categorised as ‘correct’, while results deviating from the expected interpretation 
are categorised as ‘incorrect’. 
Results must be submitted no later than 28th February 2018. 
If you do not have access to the Internet, or if you experience difficulties in entering your results, 
please contact the EQAS Coordinator directly, explaining the issues that occur. 
All results will be summarized in a report which will be publicly available. Individual results will 
be anonymous and will only be forwarded to the official GFN Regional Centre in your region. 
We are looking forward to receiving your results.  
If you have any questions or concerns, please do not hesitate to contact the EQAS 
Coordinator: 
Susanne Karlsmose Pedersen 
National Food Institute, Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby - DENMARK 
Tel: +45 3588 6601 
E-mail: suska@food.dtu.dk
Direct communication with the EQAS organisers must be in English. 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please carefully read these instructions before entering the web page. Remember that you need by 
your side the completed test forms and the breakpoint values you used.  
In general, you can browse back and forth in the pages of the database. Always remember to save 
your input before leaving a page. 
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1) Enter the WHO Collaborating Centre website (from http://www.antimicrobialresistance.dk), then 
a. Click on ‘EQAS’ 
b. Click on the link for the interactive database (http://eqas.food.dtu.dk/who) 
c. Write your username and password in lower-case letters and click on ‘Login’. 
You can find your username and password in the letter following your strains.  
Your username and password will remain unchanged in future trials. Do not hesitate to 
contact us if you experience problems with the login. 
2) Click on ‘Materials and methods’  
a. Fill in the fields relative to brand of antisera (very important because we would like to 
compare results obtained with different brands of antisera) 
b. Fill in the fields relative to the method used for antimicrobial susceptibility testing 
c. Enter the brand of materials, e.g. Oxoid 
d. Fill in the field asking whether your institute serves as a national reference laboratory  
e. In the comment field, report which antisera you think is required to complete your 
serotyping, if relevant 
f. Click on ‘Save and go to next page’ – ALWAYS remember to save each page before 
leaving it! 
3) In the data entry page ‘Routinely used breakpoints’ 
a. Fill in the fields relative to the breakpoints used routinely in your laboratory to determine 
the antimicrobial susceptibility category. Remember to use the operator keys in order to 
show – equal to (=), less than (<), less or equal to(≤), greater than (>) or greater than or 
equal to (≥). 
4) In the data entry pages ‘Salmonella strains 1-8’, 
a. SELECT the serogroup (O-group) from the drop-down list, DO NOT WRITE – Wait a few 
seconds – the page will automatically reload, so that the drop-down list in the field 
“Serotype” only contains serotypes belonging to the chosen serogroup.  
b. SELECT the serotype from the drop-down list – DO NOT WRITE – wait a few seconds 
and you can enter the antigenic formula (e.g. 1,4,5,12:i:1,2)  
c. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc.  
d. Enter the interpretation as R (resistant), I (intermediate) or S (susceptible) 
e. If you performed confirmatory tests for ESBL production, select the appropriate result. 
f. If relevant, fill in the field related to comments (e.g. which antisera you miss for complete 
serotyping)  
g. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty  
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5) In the data entry page ‘E. coli reference strain’:
a. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator
keys to show e.g. equal to (=), etc.
b. Click on ‘Save and go to next page’
6) The next page is a menu that allows you to review the input pages and approve your input and
finally see and print the evaluated results
a. Browse through the input pages and make corrections if necessary. Remember to click on
‘save and go to next page’ if you make any corrections.
b. Approve your input. Be sure that you have filled in all the results before approval, as .YOU
CAN ONLY APPROVE ONCE!. The approval blocks your data entry into the interactive
database, but allows you to see the evaluated results.
c. As soon as you have approved your input, an evaluation report will appear.
7) After browsing all pages in the report, you will find a new menu. You can choose ‘EQAS 2017
start page’, ‘Review evaluated results’ (a printer friendly version of the evaluation report is also
available) or ‘Go to WHO GFN homepage’.
End of entering your data – thank you very much! 
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SUBCULTURE AND MAINTENANCE OF 
QUALITY CONTROL STRAINS 
1 PURPOSE AND REFERENCES  
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI) has published 
guidelines for Quality Control (QC) stock culture maintenance to ensure consistent antimicrobial 
susceptibility test (AST) results.  
The following can be regarded as a summary of information that should be followed for 
subculturing and maintaining QC-strains when performing AST by broth dilution methods. For full 
information related to this subject, the following standards are relevant: M100 (Performance 
Standards for Antimicrobial Susceptibility Testing) and M7 (Methods for Dilution Antimicrobial 
Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard). 
2 DEFINITION OF TERMS 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time. 
3 IMPORTANT CONSIDERATIONS 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC.
 CLSI requires that QC be performed either on the same day or weekly (after QC-validation).
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides.
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 Periodically perform colony counts to check the inoculum preparation procedure. 
 Ideally, test values should be in the middle of the acceptable range. 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems. 
4 STORAGE OF REFERENCE STRAINS 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen (alternatively, freeze dry). 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
5 FREQUENCY OF TESTING 
Weekly vs. daily testing  
Weekly testing is possible if the laboratory can demonstrate satisfactory performance with daily 
testing according to the descriptions in the CLSI guidelines. 
 Documentation showing reference strain results from 20 or 30 consecutive test days were 
within the acceptable range. 
 For each antimicrobial/organism combination, no more one out of 20 or three out of 30 MIC 
values may be outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
If five acceptable QC results are available, no additional days of QC-testing are needed.  
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1) 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue (see http://www.sci.muni.cz) 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
 
 
 
 
 
 
 
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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